- Innovent Biologics press release (OTCPK:IVBIY): FY Total revenue RMB6,206.1 million in the year of 2023, an increase of 36.2% compared with the year of 2022; product sales revenue RMB5,728.3 million in the year of 2023, an increase of 38.4% compared with the prior year, reflecting robust demand for our innovative portfolio and the advantage of our sustainable business model.
- EBITDA loss was RMB600.1 million, a year-over-year decrease of 73.0%
Innovent Biologics reports FY results (OTCMKTS:IVBIY)
